357 related articles for article (PubMed ID: 10781781)
21. Bile acids for primary sclerosing cholangitis.
Poropat G; Giljaca V; Stimac D; Gluud C
Cochrane Database Syst Rev; 2011 Jan; 2011(1):CD003626. PubMed ID: 21249655
[TBL] [Abstract][Full Text] [Related]
22. The biochemical and histopathological effects of ursodeoxycholic acid and metronidazole on total parenteral nutrition-associated hepatic dysfunction: an experimental study.
Günsar C; Melek M; Karaca I; Sencan A; Mir E; Ortaç R; Canan O
Hepatogastroenterology; 2002; 49(44):497-500. PubMed ID: 11995481
[TBL] [Abstract][Full Text] [Related]
23. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
[TBL] [Abstract][Full Text] [Related]
24. [Treatment of cholestatic liver disease].
Pleşa A
Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):733-6. PubMed ID: 14756010
[TBL] [Abstract][Full Text] [Related]
25. [Cholestasis: therapeutic options].
Beuers U; Oswald M
Ther Umsch; 1998 Feb; 55(2):97-103. PubMed ID: 9545851
[TBL] [Abstract][Full Text] [Related]
26. Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease.
Nousia-Arvanitakis S; Fotoulaki M; Economou H; Xefteri M; Galli-Tsinopoulou A
J Clin Gastroenterol; 2001 Apr; 32(4):324-8. PubMed ID: 11276276
[TBL] [Abstract][Full Text] [Related]
27. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
Smith T; Befeler AS
Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678
[TBL] [Abstract][Full Text] [Related]
28. [Ursodeoxycholic acid: history and clinical implications].
Beuers U; Trampert DC
Ned Tijdschr Geneeskd; 2022 Sep; 166():. PubMed ID: 36300467
[TBL] [Abstract][Full Text] [Related]
29. [Bile acids in liver diseases--current indications].
Stiehl A
Ther Umsch; 1995 Oct; 52(10):682-6. PubMed ID: 7482380
[TBL] [Abstract][Full Text] [Related]
30. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases.
Festi D; Montagnani M; Azzaroli F; Lodato F; Mazzella G; Roda A; Di Biase AR; Roda E; Simoni P; Colecchia A
Curr Clin Pharmacol; 2007 May; 2(2):155-77. PubMed ID: 18690863
[TBL] [Abstract][Full Text] [Related]
31. Ursodeoxycholic acid for cystic fibrosis-related liver disease.
Cheng K; Ashby D; Smyth RL
Cochrane Database Syst Rev; 2014 Dec; (12):CD000222. PubMed ID: 25501301
[TBL] [Abstract][Full Text] [Related]
32. [The characteristics of the use of ursodeoxycholic acid in chronic diseases of the hepatobiliary system].
Dehtiar'ova II; Chernenko VV; Anokhina HA; Opanasiuk ND; Pavlik-Novol's'kyĭ T; Haĭsenko AV
Lik Sprava; 1995; (9-12):47-8. PubMed ID: 8983789
[No Abstract] [Full Text] [Related]
33. Heart and bile acids - Clinical consequences of altered bile acid metabolism.
Vasavan T; Ferraro E; Ibrahim E; Dixon P; Gorelik J; Williamson C
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1345-1355. PubMed ID: 29317337
[TBL] [Abstract][Full Text] [Related]
34. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
Beuers U
Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551
[TBL] [Abstract][Full Text] [Related]
35. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?
Hay JE
Liver Transpl Surg; 1998 Sep; 4(5 Suppl 1):S9-17. PubMed ID: 9742489
[TBL] [Abstract][Full Text] [Related]
36. Should we treat cholestatic liver disease with cholesterol synthesis inhibitors?
Schmidt HH; Manns MP
Am J Gastroenterol; 1996 Feb; 91(2):406-7. PubMed ID: 8607528
[No Abstract] [Full Text] [Related]
37. Ursodeoxycholic acid improves cholestasis in infants with cystic fibrosis.
Scher H; Bishop WP; McCray PB
Ann Pharmacother; 1997 Sep; 31(9):1003-5. PubMed ID: 9296240
[TBL] [Abstract][Full Text] [Related]
38. [Ursodeoxycholic acid in the treatment of cholestatic liver diseases].
Arrese M; Accatino L
Rev Med Chil; 1993 Apr; 121(4):439-46. PubMed ID: 8272619
[TBL] [Abstract][Full Text] [Related]
39. [Bile acids and their therapeutic use in children].
Lacaille F
Arch Pediatr; 1995 Dec; 2(12):1200-8. PubMed ID: 8548002
[TBL] [Abstract][Full Text] [Related]
40. Management of cholestatic disease in 2017.
de Vries E; Beuers U
Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
